Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) (RadioPARP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03109080
Recruitment Status : Active, not recruiting
First Posted : April 12, 2017
Last Update Posted : October 27, 2020
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Institut Curie

Tracking Information
First Submitted Date  ICMJE March 2, 2017
First Posted Date  ICMJE April 12, 2017
Last Update Posted Date October 27, 2020
Actual Study Start Date  ICMJE July 24, 2017
Actual Primary Completion Date February 17, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 5, 2017)
Determination of the Maximal Tolerated Dose of Olaparib administered with concurrent loco regional radiotherapy [ Time Frame: 2 years ]
Incidence of early Dose Limited Toxicity (DLTs: early adverse effects related to Olaparib administered with concurrent radiotherapy) to determinate the Maximal Tolerated Dose (MTD) of Olaparib administered with concurrent loco regional radiotherapy in patients who have triple negative inflammatory, loco-regional advanced or metastatic breast cancer either inoperable after neoadjuvant chemotherapy or operated patient with residual disease (after neoadjuvant chemotherapy).
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 23, 2020)
  • Incidence of Serious Adverse Events (SAEs), graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy. [ Time Frame: 2 years ]
    Incidence of Serious Adverse Events (SAEs), graded according to NCI-CTCAE version 4.03 criteria
  • Incidence and severity of Adverse Events (AEs), graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy. [ Time Frame: 2 years ]
    Incidence and severity of Adverse Events (AEs), graded according to NCI-CTCAE version 4.03 criteria
  • Incidence and severity of laboratory abnormalities, graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy. [ Time Frame: 2 years ]
    Incidence and severity of laboratory abnormalities, graded according to NCI-CTCAE version 4.03 criteria
  • Incidence of acute toxicity 2 weeks and 6 weeks after the end of radiotherapy to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy. [ Time Frame: 2 years ]
    Incidence of acute toxicity 2 weeks and 6 weeks after the end of radiotherapy
  • Incidence of late toxicity at 1 year and at 2 years as of initiation of radiation therapy to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy. [ Time Frame: 2 years ]
    Incidence of late toxicity at 1 year and at 2 years as of initiation of radiation therapy
  • Incidence of treatment discontinuations and treatment modifications due to AEs to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy. [ Time Frame: 2 years ]
    Incidence of treatment discontinuations and treatment modifications due to AEs
  • Evaluation of the Objective Response Rate (ORR) to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile [ Time Frame: 2 years ]
    Evaluation of the Objective Response Rate (ORR) to treatment
  • Evaluation of the Complete Response Rate to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile [ Time Frame: 2 years ]
    Evaluation of the Complete Response Rate to treatment
  • Evaluation of Pathological Response Rate (pRR) after salvage surgery to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile [ Time Frame: 2 years ]
    Evaluation of Pathological Response Rate (pRR) after salvage surgery
  • Evaluation of the loco-regional Progression Free Survival (l-PFS) to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile [ Time Frame: 2 years ]
    Evaluation of the loco-regional Progression Free Survival (l-PFS)
  • Evaluation of the Progression Free Survival (PFS) or Disease Free survival (DFS) according to stage of disease to evaluate patient outcome [ Time Frame: 2 years ]
    Evaluation of the Progression Free Survival (PFS) or Disease Free survival (DFS)
  • Evaluation of the distant relapse rate to evaluate patient outcome [ Time Frame: 2 years ]
    Evaluation of the distant relapse rate
  • Evaluation of patient outcome by evaluation of the Overall Survival (OS). [ Time Frame: 2 years ]
    Evaluation Overall Survival (OS).
  • Evaluation of patient outcome by evaluate disease specific survival rate. [ Time Frame: 2 years ]
    Evaluation of the disease specific survival rate.
  • Explore biomarkers of Olaparib activity in combination with concurrent radiotherapy. [ Time Frame: 2 years ]
    Exploration of biomarkers of Olaparib associated with radiotherapy on biopsies.
Original Secondary Outcome Measures  ICMJE
 (submitted: April 5, 2017)
  • Incidence of Serious Adverse Events (SAEs), graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy. [ Time Frame: 2 years ]
    Incidence of Serious Adverse Events (SAEs), graded according to NCI-CTCAE version 4.03 criteria
  • Incidence and severity of Adverse Events (AEs), graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy. [ Time Frame: 2 years ]
    Incidence and severity of Adverse Events (AEs), graded according to NCI-CTCAE version 4.03 criteria
  • Incidence and severity of laboratory abnormalities, graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy. [ Time Frame: 2 years ]
    Incidence and severity of laboratory abnormalities, graded according to NCI-CTCAE version 4.03 criteria
  • Incidence of acute toxicity 2 weeks and 6 weeks after the end of radiotherapy to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy. [ Time Frame: 2 years ]
    Incidence of acute toxicity 2 weeks and 6 weeks after the end of radiotherapy
  • Incidence of late toxicity at 1 year and at 2 years as of initiation of radiation therapy to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy. [ Time Frame: 2 years ]
    Incidence of late toxicity at 1 year and at 2 years as of initiation of radiation therapy
  • Incidence of treatment discontinuations and treatment modifications due to AEs to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy. [ Time Frame: 2 years ]
    Incidence of treatment discontinuations and treatment modifications due to AEs
  • Evaluation of the Objective Response Rate (ORR) to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile [ Time Frame: 2 years ]
    Evaluation of the Objective Response Rate (ORR) to treatment
  • Evaluation of the Complete Response Rate to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile [ Time Frame: 2 years ]
    Evaluation of the Complete Response Rate to treatment
  • Evaluation of Pathological Response Rate (pRR) after salvage surgery to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile [ Time Frame: 2 years ]
    Evaluation of Pathological Response Rate (pRR) after salvage surgery
  • Evaluation of the loco-regional Progression Free Survival (l-PFS) to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile [ Time Frame: 2 years ]
    Evaluation of the loco-regional Progression Free Survival (l-PFS)
  • Evaluation of the Progression Free Survival (PFS) or Disease Free survival (DFS) according to stage of disease to evaluate patient outcome [ Time Frame: 5 years ]
    Evaluation of the Progression Free Survival (PFS) or Disease Free survival (DFS)
  • Evaluation of the distant relapse rate to evaluate patient outcome [ Time Frame: 5 years ]
    Evaluation of the distant relapse rate
  • Evaluation of patient outcome by evaluation of the Overall Survival (OS). [ Time Frame: 5 years ]
    Evaluation Overall Survival (OS).
  • Evaluation of patient outcome by evaluate disease specific survival rate. [ Time Frame: 5 years ]
    Evaluation of the disease specific survival rate.
  • Explore biomarkers of Olaparib activity in combination with concurrent radiotherapy. [ Time Frame: 3 years ]
    Exploration of biomarkers of Olaparib associated with radiotherapy on biopsies.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)
Official Title  ICMJE A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease
Brief Summary A Phase I of Olaparib with Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (triple negative breast cancer) or Patient With Operated TNBC with Residual Disease.
Detailed Description Open label phase I, dose escalation trial for patients with triple negative inflammatory, loco-regional advanced or metastatic breast cancer either inoperable after neoadjuvant chemotherapy or operated with residual disease (after neoadjuvant chemotherapy).
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Breast Neoplasms, Triple-Negative
  • Breast Neoplasm Malignant Female
  • Radiotherapy Side Effect
Intervention  ICMJE
  • Drug: Olaparib
    five levels of dose, per os administration, twice daily each day
    Other Name: PARP (Poly (Adenosine diphosphate [ADP]-Ribose) Polymerase) inhibitor, Lynparza, AZD-2281
  • Radiation: Radiation therapy
    3D conformal radiotherapy or intensity-modulated radiotherapy (IMRT), Simultaneous Integrated Boost (SIB), postoperative radiotherapy
    Other Name: Radiotherapy
Study Arms  ICMJE Experimental: Olaparib + radiation therapy
One week of Olaparib alone followed by 5 weeks of Olaparib and concurrent loco-regional radiotherapy. Five levels of dose of Olaparib are expected.
Interventions:
  • Drug: Olaparib
  • Radiation: Radiation therapy
Publications * Loap P, Loirat D, Berger F, Ricci F, Vincent-Salomon A, Ezzili C, Mosseri V, Fourquet A, Ezzalfani M, Kirova Y. Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial. Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):436-440. doi: 10.1016/j.ijrobp.2020.09.032. Epub 2020 Sep 21.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: April 5, 2017)
24
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE April 2022
Actual Primary Completion Date February 17, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Woman aged >18 years.
  2. Histologically confirmed triple negative breast cancer with loco-regional radiotherapy indication :

    1. Non-operated with either:

      1. Inflammatory breast cancer in progression during neoadjuvant chemotherapy or inoperable after neoadjuvant chemotherapy.
      2. Loco-regional advanced breast cancer in progression during neoadjuvant chemotherapy or inoperable after neoadjuvant chemotherapy (T ≥ 3 and/or N ≥ 1; with evaluable disease according to RECIST 1.1 criteria).
      3. Non operable metastatic breast cancer (all T, all N, M1; with evaluable disease according to RECIST 1.1 criteria) needing local and regional treatment in case of good metastatic control after chemotherapy.
    2. Or patient operated after neoadjuvant treatment and surgery with residual disease (non-pCR and/or pN+ disease).
  3. Neoadjuvant chemotherapy (containing anthracyclines or taxanes or the combination of both or containing platinum-based chemotherapy) willingness to discontinue any cytotoxic chemotherapeutic agents, immunotherapy, and targeted therapies at least two weeks prior to start of Olaparib.
  4. ECOG performance status < 2.
  5. Life expectancy greater than 6 months.
  6. Adequate hematologic, renal and hepatic function (assessed within the two weeks prior to registration and within the month prior to the commencement of protocol treatment). For patients who have stopped chemotherapy two weeks prior to protocol treatment, hematologic function must be re-assessment 1 or 2 days before the first Olaparib intake:

    1. Haemoglobin ≥ 10.0 g/dL.
    2. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L.
    3. White Blood Cells (WBC) > 3 x 109/L.
    4. Platelet count ≥ 100 x 109/L.
    5. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (except in case of Gilbert syndrome).
    6. AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5 x ULN.
    7. Patients must have Creatinine Clearance estimated using the Cockcroft-Gault equation of ≥ 51 mL/min
  7. Urine or serum negative pregnancy test within two weeks prior to registration for non-postmenopausal patients. Negative pregnancy test confirmed within 1 or 2 days prior to first Olaparib intake.
  8. For woman with child-bearing potential, an efficacious contraception following sponsor recommendations must be used during the whole treatment period and up to three months after the last Olaparib administration.
  9. Ability to swallow and retain oral medications without gastrointestinal disorders likely to interfere with absorption of the study medication.
  10. Affiliation to the French Social Security System.
  11. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Radiation therapy: prior history of radiation therapy to the ipsilateral breast and/or regional nodes (except prior radiation therapy to other sites).
  2. Patient with unresolved or unstable, NCI-CTCAE v4.03 (National Cancer Institute Common Toxicity Criteria for Adverse Events) Grade 3 or greater toxicity from prior administration of prior anti-cancer treatment.
  3. Patient with clinically and uncontrolled significant comorbidity: major cardiac, respiratory, renal, hepatic, gastrointestinal, hematologic or neurological/psychiatric disease or disorder, including but not limited to: active uncontrolled infection; symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia; any other illness condition(s) that could exacerbate potential toxicities, require excluded therapy for management, or limit compliance with study requirements.
  4. Patient with second primary cancer, except : adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years.
  5. Concomitant anti-cancer treatment during protocol treatment and/or not completed at least 2 weeks prior to Olaparib initiation, except bisphosphonates and RANK inhibitors without restriction even during protocol treatment as long as these where started at least 4 weeks prior to study treatment initiation.
  6. Any previous treatment with a PARP (Poly (Adenosine diphosphate [ADP]-Ribose) Polymerase) inhibitor, including Olaparib.
  7. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Olaparib.
  8. Patient being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A (Rifabutin, Rifampicin, Clarithromycin, Ketoconazole, Itraconazole, Voriconazole, Ritonavir, Telithromycin) within the last 7 days before first Olaparib intake.
  9. Resting ECG with QTc > 470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.
  10. Blood transfusions within 14 days prior to treatment start.
  11. Patient with myelodysplastic syndrome / acute myeloid leukaemia.
  12. Pregnant or breastfeeding woman.
  13. Patient already included in another clinical trial with an investigational drug.
  14. Patient individually deprived of liberty or placed under the authority of a tutor.
  15. Patient with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03109080
Other Study ID Numbers  ICMJE IC 2016-01 RadioPARP
2016-001837-28 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Institut Curie
Study Sponsor  ICMJE Institut Curie
Collaborators  ICMJE AstraZeneca
Investigators  ICMJE
Study Director: Youlia KIROVA, MD Institut Curie
PRS Account Institut Curie
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP